# A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo

> **NCT01803035** · PHASE2 · COMPLETED · sponsor: **Lytix Biopharma AS** · enrollment: 210 (estimated)

## Conditions studied

- Non-bullous Impetigo

## Interventions

- **DRUG:** LTX-109 1 %
- **DRUG:** LTX-109 2 %
- **DRUG:** Placebo gel

## Key facts

- **NCT ID:** NCT01803035
- **Lead sponsor:** Lytix Biopharma AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2014-03
- **Final completion:** 2014-04
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2014-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01803035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01803035, "A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01803035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*